The Study on the Expression of ICAM-1 in Transitional Cell Carcinoma of Bladder.
- Author:
Chung Ho CHO
1
;
Jung Weon SHIM
;
Young Gu LEE
Author Information
1. Department of Urology, College of Medicine, Hallym University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Bladder;
Transitional cell carcinoma;
ICAM-1
- MeSH:
Carcinoma, Transitional Cell*;
Cell Adhesion;
Humans;
Intercellular Adhesion Molecule-1*;
Mycobacterium bovis;
Paraffin;
Survival Rate;
Urinary Bladder*
- From:Korean Journal of Urology
1999;40(2):187-192
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: ICAM-1(Intercellular Adhesion Molecule-1) is a cell adhesion molecule which facilitates the binding of LAK(Lymphokine Activated Killer )cell and cytotoxic T cell to tumor cell. This study investigates the role of ICAM-1 in transitional cell carcinoma(TCC) of bladder. MATERIALS AND METHODS: Immunohistochemical stain for ICAM-1 was done in 42 paraffin embedded tissue of primary TCC of bladder. And we compared the expression of ICAM-1 and the degree of immune cell infiltration, tumor grade, stage and survival rate of the patients. RESULTS: Immunohistochemical examination demonstrated expression of ICAM-1 on 17 of 42 bladder TCC but not on five normal transitional cells. The more frequently immune cells infiltrated, the more frequently ICAM-1 was expressed(p=0.018). And ICAM-1 was frequently expressed in higher histopathological grade and higher stage tumors(p=0.035, p=0.002). Survival rate was lower in ICAM-1 expressed tumors than in ICAM-1 non-expressed tumors even though it is insignificant statistically(p=0.11). CONCLUSIONS: These results suggest that ICAM-1 plays an important role on immune therapy for bladder TCC, and ICAM-1 expression in bladder TCC could be another prognostic factor and used as a response predictor for immune therapy such as intravesical BCG instillation.
